In 2024, Wegovy sales reached $8 billion, while Ozempic, its other Semaglutide product, brought in $17 billion. Lilly’s Mounjaro recorded $11.5 billion in global sales in 2024, an increase of 124% ...

Eli Lilly (LLY) stock in focus as the company launches Mounjaro Kwikpen in India, intensifying competition with Novo ...

In India, home to 74 million diabetes patients, a range of supplements is being marketed as natural GLP-1 alternatives, but ...

Researchers find programme that could improve IVF outcomes - Women who took part in a weight loss programme had a 21 per cent ...

Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets ...

(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...

WEIGHT loss jabs are weaving themselves into the fabric of our daily lives and chances are you know someone taking them – or ...

Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...

European drug regulators classify NAION as a 'very rare' side effect of semaglutide — the active ingredient in Ozempic, Wegovy. The risk often emerged after two years of use ...

SHAMELESS legend Tina Malone branded herself a “big fat bird” as she revealed the real reason she lost weight and dropped to ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...